Reduced Expression of Perlecan in the Aorta of Secondary Hyperparathyroidism Model Rats with Medial Calcification

REFERENCES

• Goodman WG, Goldin J, Kuizon BD, Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483.
   PubMed Web of Science ®Google Scholar
• Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938–942.
   PubMed Web of Science ®Google Scholar
• London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18:1731–1740.
   PubMed Web of Science ®Google Scholar
• Raggi P, Boulay A, Chasan-Taber S, Cardiac calcification in adult hemodialysis patients: A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol. 2002;39:695–701.
   PubMed Web of Science ®Google Scholar
• Goodman WG, London G, Amann K, Vascular calcification in chronic kidney disease. Am J Kidney Dis. 2004;43:572–579.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in hemodialysis patients. Nephrol Dial Transplant. 2004;19:1489–1496.
   PubMed Web of Science ®Google Scholar
• Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91:1800–1809.
   PubMed Web of Science ®Google Scholar
• Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest. 1994;93:2393–2402.
   PubMed Web of Science ®Google Scholar
• Shanahan CM, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME. Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: Evidence for smooth muscle cell-mediated vascular calcification. Circulation. 1999;100:2168–2176.
   PubMed Web of Science ®Google Scholar
• Steitz SA, Speer MY, Curinga G, Smooth muscle cell phenotypic transition associated with calcification: Upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89:1147–1154.
   PubMed Web of Science ®Google Scholar
• Jono S, McKee MD, Murry CE, Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:E10–E17.
   PubMed Web of Science ®Google Scholar
• Campbell JH, Campbell GR. Culture techniques and their applications to studies of vascular smooth muscle. Clin Sci (Lond). 1993;85:501–513.
   PubMed Web of Science ®Google Scholar
• Tran PK, Agardh HE, Tran-Lundmark K, Reduced perlecan expression and accumulation in human carotid atherosclerotic lesions. Atherosclerosis. 2007;190:264–270.
   PubMed Web of Science ®Google Scholar
• Edwards IJ, Wagner JD, Vogl-Willis CA, Litwak KN, Cefalu WT. Arterial heparan sulfate is negatively associated with hyperglycemia and atherosclerosis in diabetic monkeys. Cardiovasc Diabetol. 2004;29:3–6.
   Google Scholar
• Yang L, Butcher M, Simon RR, Osip SL, Shaughnessy SG. The effect of heparin on osteoblast differentiation and activity in primary cultures of bovine aortic smooth muscle cells. Atherosclerosis. 2005;179:79–86.
   PubMedGoogle Scholar
• Jiao X, Billings PC, O'Connell MP, Kaplan FS, Shore EM, Glaser DL. Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. J Biol Chem. 2007;282:1080–1086.
   PubMedGoogle Scholar
• Iozzo RV, Cohen IR, Grässel S, Murdoch AD. The biology of perlecan: The multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J. 1994;302:625–639.
   PubMed Web of Science ®Google Scholar
• Kimura S, Cheng J, Toyoshima K, Oda K, Saku T. Basement membrane heparan sulfate proteoglycan (perlecan) synthesized by ACC3, adenoid cystic carcinoma cells of human salivary gland origin. J Biochem. 1999;125:406–413.
   PubMedGoogle Scholar
• Groffen AJ, Veerkamp JH, Monnens LA, van den Heuvel LP. Recent insights into the structure and functions of heparan sulfate proteoglycans in the human glomerular basement membrane. Nephrol Dial Transplant. 1999;14:2119–2129.
   PubMedGoogle Scholar
• Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L. Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? J Clin Invest. 1997;99:2062–2070.
   PubMed Web of Science ®Google Scholar
• Segev A, Nili N, Strauss BH. The role of perlecan in arterial injury and angiogenesis. Cardiovasc Res. 2004;63:603–610.
   PubMed Web of Science ®Google Scholar
• Pillarisetti S. Lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan) and atherogenicity. Trends Cardiovasc Med. 2000;10:60–65.
   PubMed Web of Science ®Google Scholar
• Kinsella MG, Tran PK, Weiser-Evans MC, Reidy M, Majack RA, Wight TN. Changes in perlecan expression during vascular injury: Role in the inhibition of smooth muscle cell proliferation in the late lesion. Arterioscler Thromb Vasc Biol. 2003;23:608–614.
   PubMed Web of Science ®Google Scholar
• Paka L, Goldberg IJ, Obunike JC, Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. An underlying mechanism for the modulation of smooth muscle cell growth? J Biol Chem. 1999;274:36403–36408.
   PubMedGoogle Scholar
• Stevens RL, Colombo M, Gonzales JJ, Hollander W, Schmid K. The glycosaminoglycans of the human artery and their changes in atherosclerosis. J Clin Invest. 1976;58:470–481.
   PubMed Web of Science ®Google Scholar
• Pillarisetti S, Paka L, Obunike JC, Berglund L, Goldberg IJ. Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest. 1997;100:867–874.
   PubMed Web of Science ®Google Scholar
• Tammi M, Seppala PO, Lehtonen A, Mottonen M. Connective tissue components in normal and atherosclerotic human coronary arteries. Atherosclerosis. 1978;29:191–194.
   PubMed Web of Science ®Google Scholar
• Hollmann J, Schmidt A, von Bassewitz DB, Buddecke E. Relationship of sulfated glycosaminoglycans and cholesterol content in normal and arteriosclerotic human aorta. Arteriosclerosis. 1989;9:154–158.
   PubMedGoogle Scholar
• Wasty F, Alavi MZ, Moore S. Distribution of glycosaminoglycans in the intima of human aortas: Changes in atherosclerosis and diabetes mellitus. Diabetologia. 1993;36:316–322.
   PubMed Web of Science ®Google Scholar
• Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y. Perlecan is essential for cartilage and cephalic development. Nat Genet. 1999;23:354–358.
   PubMed Web of Science ®Google Scholar
• Bhandari M, Hirsh J, Weitz JI, Young E, Venner TJ, Shaughnessy SG. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Hemost. 1998;80:413–417.
   PubMed Web of Science ®Google Scholar
• Sonawane S, Kasbekar N, Berns JS. The safety of heparins in end-stage renal disease. Semin Dial. 2006;19:305–310.
   PubMedGoogle Scholar
• Vogl-Willis CA, Edwards IJ. High glucose-induced alterations in subendothelial matrix perlecan leads to increased monocyte binding. Arterioscler Thromb Vasc Biol. 2004;24:858–863.
   PubMedGoogle Scholar
• Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004;95:560–567.
   PubMed Web of Science ®Google Scholar